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Objective: Recent results after endovascular abdominal aortic aneurysm repair (EVAR) have brought into question its
value in patients deemed at high-risk for surgical intervention. TheDepartment of Veteran Affairs (VA)National Surgical
Quality Improvement Program (NSQIP) is the largest prospectively collected and validated United States surgical
database representing current clinical practice. The purpose of our study was to evaluate outcomes after elective EVAR
performed in high-risk veterans.
Methods: Using NSQIP data from 123 participating VA hospitals, we retrospectively evaluated patients who underwent
elective aneurysm repair fromMay 2001 to December 2004. High-risk criteria were used to identify a cohort for analysis
(EVAR, n  788; open, n  1580). High-risk criteria analyzed included age >60 years, American Society of
Anesthesiology (ASA) classification 3 or 4, and the comorbidity variables of history of cardiac, respiratory, or hepatic
disease, cardiac revascularization, renal insufficiency, and low serum albumin level. Our primary end points were 30-day
and 1-year all-cause mortality, and we evaluated a secondary end point of perioperative complications. Statistical analysis
included univariate analysis and multivariate modeling.
Results: Veterans who were classified as high-risk underwent elective EVAR with significantly lower 30-day (3.4% vs
5.2%, P  .047) and 1-year all-cause mortality (9.5% vs 12.4%, P  .038) than patients having open repair. EVAR
was associated with a decrease in 30-day postoperative mortality (adjusted odds ratio [OR], 0.65; 95% confidence
interval [CI], 0.42 to 1.03; P  .067) as well as 1-year mortality (adjusted OR, 0.68; 95% CI, 0.51 to 0.91; P 
.0094) despite the presence of severe comorbid conditions. The risk of perioperative complications was significantly
lower after EVAR (16.2% vs 31.0%; P < .0001; adjusted OR, 0.41; 95% CI, 0.33 to 0.52; P < .0001). A subset
analysis of higher-risk patients (ASA 4 and the above comorbidity variables) still demonstrated an acceptable 30-day
mortality rate.
Conclusion: In veterans deemed high-risk for surgical therapy, outcomes after elective EVAR are excellent, and the
procedure is relatively safe in this special patient population. Our retrospective data demonstrate that patients with
considerable medical comorbidities and infrarenal abdominal aortic aneurysms benefit from and should be considered for
primary EVAR. (J Vasc Surg 2007;45:227-34.)From the Michael E. DeBakey Department of Surgery, Baylor College of
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(EVAR) is a major advance in minimally invasive surgical
technology because of the potential for reducing perioper-
ative morbidity and mortality as well as recovery time,
especially in patients deemed at high surgical risk by con-
ventional open standards. The rapid evolution of endolu-
minal devices and surgical and anesthetic techniques during
the past decade has allowed higher-risk patients, including
octogenarians and others considered medically unfit for
conventional open repair, to be offered EVAR as an alter-
native to observation alone.
Many retrospective, single institution studies docu-
menting acceptable morbidity andmortality rates following
EVAR in special high-risk patient populations are available
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risk patients using the Society of Vascular Surgery data-
base for EVAR (registry established in 1998)8 concluded
that endovascular repair is safe and effective in preventing
aneurysm rupture.9
Conversely, in prospective, randomized trials compar-
ing EVAR with open surgical repair, patients who were
considered to be at excessive surgical risk and medically
unfit for conventional open repair were excluded from
participation.10,11 In the recently published EVAR Trial 2
performed in the United Kingdom, this subset of excluded
patients were further studied by being randomized to either
EVAR or no intervention.12 The 30-day mortality rate of
9% and the 4-year mortality of 64% are both much higher
than has been previously reported in high-risk patient co-
horts. Furthermore, the investigators found no survival
advantage after repair compared with those who had obser-
vation alone.
This prospective and randomized trial, with its level
1evidence, has thus challenged the promising outcomes
considered to be associated with EVAR in high-risk indi-
viduals. These data have resulted in suggestions that per-
haps EVAR should not be performed in select high-risk
individuals owing to the possibility of poor outcomes and
lack of improvement in survival, both at excessive financial
expenditure.
In the United States, no prospective, randomized trial
similar to EVAR Trial 2 has been completed to date. The
availability of data that demonstrate positive outcomes with
EVAR in high-risk patients, who represent those treated in
routine surgical practices, is paramount to physician, pa-
tient, and policy-makers alike. The National Surgical Qual-
ity Improvement Program (NSQIP) represents a large,
validated, prospective data set that is organized and imple-
mented through the Department of Veteran Affairs (VA).
The purpose of our study was to compare postoperative
mortality and complications as well as survival in high-risk
patients undergoing elective EVAR vs open repair within a
national publicly funded health care system using a large
prospective cohort.
PATIENTS AND METHODS
Data sources and sample. All patients who under-
went either EVAR or open abdominal aortic aneurysm
repair between May 1, 2001, and December 31, 2004,
were identified through the VA NSQIP database13 of sur-
gical procedures performed at 123 participating VA hospi-
tals. We chose this time frame because beforeMay 2001, no
suitable current procedural terminology (CPT) codes ex-
isted in the database for EVAR, although endovascular
grafting systems were approved by the US Food and Drug
Administration and became commercially available in Sep-
tember 1999.
Patients undergoing elective repair were defined by the
primary International Classification of Diseases, 9th Revi-
sion, Clinical Modification (ICD-9-CM) diagnostic code
441.4 (intact, nonruptured abdominal aortic aneurysm).
Open AAA repairs were defined by CPT codes 35081 and35102. EVAR was defined by codes 34800, 34802, and
34804. Patients with secondary diagnostic codes for rup-
tured AAA or thoracic or thoracoabdominal aortic aneu-
rysm were excluded from the analysis. CPT codes repre-
senting open repair after EVAR (34830, 34831, 34832)
were also excluded from primary analysis.
The NSQIP database contains very detailed, prospec-
tively collected clinical data on all patients undergoing
major surgical procedures within the VA.13 At the time of
surgery, patients are enrolled in NSQIP, and baseline de-
mographic, preoperative laboratory, and clinical informa-
tion is collected by dedicated trained nurse reviewers. Ad-
ditional perioperative data are prospectively collected by
the nurses, including 30-day morbidity andmortality infor-
mation.
To supplement the information in the NSQIP records
with longer-term utilization and vital statistics data, we
used encrypted Social Security numbers, date of admission,
date of discharge, and primary operative date to link the
NSQIP database with the VA Patient Treatment File
(PTF), which contains abstracts of all patients discharged
from all VA hospitals. To obtain additional information, we
similarly linked the VA Outpatient Clinic File (OPC),
which contains records for every outpatient visit to a VA
facility. Linkage to the VA Beneficiary Identification Record
Locator System (BIRLS) was performed to assess mortality
data. The sensitivity of the BIRLS to estimate death rates of
inpatients has been demonstrated in several studies to be
approximately 87% to 95%.14,15 Approval for the study was
obtained from the Baylor College ofMedicine Institutional
Review Board and the Michael E. DeBakey VA Medical
Center Research and Development Review Committee.
Definition of independent variables. Patient demo-
graphic data are recorded prospectively in the NSQIP
database, including age, gender, race, and hospital location.
Comorbid conditions known to have an influence on the
risk of cardiovascular morbidity and mortality were chosen
for analysis.1,16,17 These independent variables were de-
fined using NSQIP definitions and the ICD-9-CM codes.
Within NSQIP, nurse reviewers recorded diabetes (persons
using insulin or oral hypoglycemic agent), renal dysfunc-
tion or dialysis dependence, hepatic dysfunction, history of
malignancy, history of congestive heart failure during the
month preceding surgery, history of stoke or transient
ischemic attacks, functional status, and tobacco use within
the year preceding AAA repair.
We additionally identified 24 individual comorbid con-
ditions and included a separate variable for elevated creati-
nine (2.0 mg/dL) that was based on the Revised Cardiac
Risk Index.17 American Society of Anesthesiology (ASA)
classification was included as a subjective estimation of a
patient’s preoperative risk and baseline comorbid status.
Both the inpatient (PTF) and outpatient (OPC) files were
searched for matching ICD-9-CM codes 1 year before the
operation date to ensure accuracy of comorbidity status.
Definition of a high-risk cohort. High-risk criteria
were used to identify a cohort for analysis. Minimum crite-
ria for entry into our study included age60 years and ASA
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to the comorbidity variables of history of cardiac, respira-
tory, or hepatic disease, cardiac revascularization, renal
insufficiency, and low serum albumin. Because hypoalbu-
minemia has been shown to be associated with adverse
surgical outcomes,18,19 preoperative serum albumin con-
centration was analyzed as an independent variable. We
defined a low albumin level of3.4 g/L, which represents
the 10th percentile in this cohort.
Outcome measures. The outcomes of interest in-
cluded 30-day and 1-year mortality and any perioperative
(30-day) complications. The 30-day mortality was ob-
tained from the NSQIP database, and 1-year mortality was
calculated using death dates obtained from BIRLS and the
PTF.
Perioperative complications from theNSQIP (seeAppen-
dix, online only) were aggregated into categories, including
adverse cardiac events, renal dysfunction, pulmonary compli-
cations, wound complications, neurologic complications,
postoperative bleeding requiring transfusion, and graft fail-
ure.20 Unfortunately, the original NSQIP guideline does
not have a strict definition for what constitutes a “graft
failure” except for a return to the operating room. This
term is not specific to endovascular devices; thus, this
variable may be misleading and difficult to analyze in a
meaningful way. Within the data sets used, specific analysis
of secondary interventions was not possible.
Postoperative length of stay and intensive care unit
length of stay were calculated by using the date of surgical
repair as the index date. Complete vital status information
(either via death or follow-up records) was available on all
patients at 30 days and at 1 year.
Statistical analysis. All clinical outcomes of interest
were tested for association with type of AAA repair and with
the presence of the six additional high-risk comorbidities as
defined. The effect of type of operation performed was then
tested for its unique association with the morbidity and
mortality outcomes (30-day, 365-day, any complication),
after adjusting for the number of high-risk comorbidities
and 20 additional demographic and clinical covariates20,21
in multivariable logistic regression models. A significance
level of 0.10 was required to stay in the final model. This
level was selected arbitrarily to capture as many possible
confounding factors that might be strongly associated with
both the selection of EVAR and postoperative outcomes.
Models were assessed for goodness of fit by the Hosmer-
Lemeshow statistic and for discrimination by the c-index.22-24
Additional assessment of time to death was made using
Kaplan-Meier estimators and log-rank tests. All P values
reported are two-sided.
RESULTS
Patient population. From the NSQIP database, we
initially identified 2966 elective repairs of nonruptured
aneurysms that occurred between the time period of inter-
est and that met the minimum criteria of age60 and ASA
class 3 or 4. Further classification with our high-risk criteria
narrowed the cohort for analysis to 788 patients whounderwent EVAR and 1580 patients who underwent open
repair.
Basic demographic characteristics of the sample and
prevalence of high-risk comorbid conditions are summa-
rized in Table I. EVAR patients were on average age about
1 year older (P  .001). Less than 1% of all patients were
women. Racial/ethnicity distribution did not vary by type
of surgery; more than three quarters of all patients were
white, with at least 7% black and 2% Hispanic. Approxi-
mately 58% of the patients had respiratory disease, 20% had
prior revascularization, about 75% had cardiac disease, 4%
to 5% had hepatic disease, and 16% had a low serum
albumin level. With the exception of renal disease, which
was more frequent among open repair patients (P .014),
the prevalence of high-risk conditions was similar for pa-
tients receiving both types of surgery.
Outcome measures. The crude, unadjusted associa-
tion of type of surgery with clinical outcomes, and the risk
associated with increasing number of high-risk comorbidi-
ties are presented in Table II. The 30-day mortality rates
were 5.2% for patients undergoing open repair compared
with 3.4% for patients receiving EVAR (P  .047). One-
year mortality and perioperative complications were simi-
larly reduced in EVAR patients (P  .038 and P  .0001,
respectively). About 20% of patients undergoing each type
of surgery had none of the additional high-risk comorbidi-
ties when theNSQIP data were cross-linked to the PTF and
OPC data sets, indicating that four fifths had at least one of
the high-risk conditions. Our final analysis included only
patients identified from the NSQIP that had at least one of
the high-risk conditions in addition to age 60 years and
ASA class 3 or 4.
Table II also presents the adjusted odds ratios (OR)
Table I. Demographic characteristics of sample and
prevalence of high-risk comorbid conditions
Open
n  1580
(%)
EVAR
n  788
(%) P
Age (years)* 71.8  6.4 72.9  6.7 .0001
Gender
Male 1568 (99.2) 798 (99.4) .73
Race/ethnicity 0.26
White 1281 (81.1) 606 (76.9)
Black 104 (6.6) 58 (7.4)
Hispanic 34 (2.2) 14 (1.8)
Other/unknown 161 (10.2) 110 (14.0)
High-risk conditions
Respiratory 916 (58.8) 455 (57.7) .91
Hepatic 79 (5.0) 36 (4.6) .64
Cardiac 1198 (75.8) 596 (75.6) .92
Prev cardiac
revascularization 321 (20.3) 168 (21.3) .57
Renal 106 (6.7) 33 (4.2) .014
Low serum albumin 251 (15.9) 132 (16.8) .59
EVAR, Endovascular aneurysm repair.
*Age is presented as mean (standard deviation); all other values are given as
number (%); percentages for high-risk conditions do not total 100% because
patients may have more than one condition.and 95% confidence intervals (CI) for the association of
rval.
and c
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number of high-risk conditions and additional covariates.
Risk of all clinical outcomes was reduced in patients under-
going EVAR compared with patients receiving open repair:
theORs for EVARwere 0.65 for 30-daymortality (95%CI,
0.42 to 1.03), 0.68 for 1-year mortality (95% CI, 0.51 to
0.91), and 0.41 for any complication (95% CI, 0.33 to
0.52). Among patients receiving open repair, this converts
to a relative increased risk of 1.56 for 30-day mortality,
1.47 for 1-year mortality, and 2.33 for complications.
In stratified analyses (Fig 1, 2, and 3), the risk of all
clinical outcomes increased dramatically as the number of
these conditions increased and was generally lower among
patients receiving EVAR across strata. We were able to
obtain 2-year data on patients in the cohort via linkage with
the BIRLS database. Fig 4 shows the survival advantage in
EVAR patients compared with open repair for 2-year follow-
up (log-rank test 2  5.23, P  .0222). In addition,
postoperative length of stay averaged 5.6 days for patients
receiving EVAR compared with 12.6 days for patients
receiving open repair (data not shown, P  .0001).
Highest-risk cohort. A separate analysis of only the
721 patients with ASA class 4 showed a crude 30-day
mortality rate of 5.6% (14/249) in EVAR patients and
7.0% (33/472) in open repair patients (P  .48). The
1-year crude mortality rates were 12.8% in EVAR patients
and 16.7% in open patients (P .17). Although neither the
Fig 1. Bar graph shows the unadjusted association between types
of surgery, either endovascular aneurysm repair (EVAR) or open
repair, and 30-day mortality rates stratified by number of surgical
risk factors. The P value reflects comparison between Open (clear
bars) and EVAR (shaded bars) within the level of risk factors.
Table II. Outcomes, adjusted odds ratios, and 95% confid
outcomes*
EVAR n  788 (%) Open n 
30-day mortality 27 (3.4) 83 (
1-year mortality 75 (9.5) 196 (
Any complication 128 (16.2) 490 (
EVAR, Endovascular aneurysm repair; OR, odds ratio; CI, confidence inte
*Adjusted for count of high-risk conditions and 20 additional demographic30-day nor 1-year rates were statistically different, a bene-ficial trend was seen with EVAR. Furthermore, the propor-
tion of patients with complications was significantly re-
duced in the EVAR patients (22.1%) compared with open
repair patients (35.8%; P  .0002).
DISCUSSION
In this unique cohort of US veterans, representing
routine surgical practice, high-risk patients presenting
for elective AAA repair who underwent EVAR had sta-
tistically significantly lower risk-adjusted perioperative
mortality rates, lower complication rates, improved sur-
vival, and shorter lengths of stay compared to patients
having open repair. Furthermore, even the highest risk
patients, those with the ASA 4 classification, were found
to benefit from EVAR with lower mortality and morbid-
ity rates compared to open surgical counterparts. Our
findings with regard to outcomes following EVAR and
open AAA repair are consistent with several other pub-
lished observational studies, with additional survival in-
formation via database linkage.2-5,9,25,26 The results
herein are also similar to a previous study we published
on a smaller, veteran cohort which included all elective
aneurysm repairs. The similarities in findings are not
surprising as others have suggested that patients present-
ing for treatment in the VA system may have more
comorbidities and a greater illness burden than non-VA
patients.27 Thus, a greater percentage of patients will
Fig 2. Bar graph shows the unadjusted association between types
of surgery, either endovascular aneurysm repair (EVAR) or open
repair, and 1-year mortality rates stratified by number of surgical
risk factors. The P value reflects comparison between Open (clear
bars) and EVAR (shaded bars) within the level of risk factors.
intervals for the association of type of surgery with
(%) OR* (EVAR) 95% CI P
0.65 0.42, 1.03 0.067
0.68 0.51, 0.91 .0094
0.41 0.33, 0.52 .0001
linical covariables.ence
1580
5.2)
12.4)
31.0)match a “high-risk” definition. The fact that our study
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cifically defined high-risk patient cohort is vital to deter-
mining the applicability, and potentially the reimburse-
ment, of EVAR for this special patient population.
The NSQIP was prompted in 1986 by a congressional
mandate and officially established in 1994 by the Veterans
Health Administration.13 Though there are inherent defi-
ciencies within retrospective data analyses, the NSQIP me-
ticulous data collection methods and their effectiveness
have been validated in multiple studies.28-30 We used the
NSQIP database to identify our cohort based upon set
criteria as outlined herein. With data from 123 institutions,
the information contained within the NSQIP is robust with
respect to variability in surgical techniques and skills as well
as in cohort size, albeit procedure (and device) specific
variables are not included. Moreover, data entry into
NSQIP does not have the patient or aneurysm morpho-
logic exclusion criteria that randomized trials contain, in-
Fig 3. Bar graph shows the unadjusted association between types
of surgery, either endovascular aneurysm repair (EVAR) or open
repair, and perioperative complication rates stratified by number of
surgical risk factors. The P value reflects comparison between
Open (clear bars) and EVAR (shaded bars) within the level of risk
factors. There are fewer complications at all risk levels following
EVAR.
Number at risk
Open 1580        1446       1418       1384       1360       1336 1319
EVAR 788          747         731         713         698       690        683
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Fig 4. Kaplan-Meier analysis shows a benefit to patients having
endovascular aneurysm repair (EVAR; thick line) that remains
greater than open repair (thin line) even at 2 years.creasing the generalizability of our findings beyond VApatients. Furthermore, we cross-referenced the NSQIP
data with both the inpatient and outpatient VA files to
ensure accuracy of comorbidity and ICD-9 code reporting
and thus, the actual presence of discrete co-morbidities of
interest.
The criteria used for defining what constitutes a “high-
risk” patient differ among clinical reports. Whether the
patient is considered at “high-risk” or medically unfit for a
specific operation, such as open AAA repair, may depend
upon either specific criterion or upon guidelines established
by the trial designers. In prospective, randomized trials
comparing open to endovascular AAA repair, such as the
Dutch and United Kingdom (UK) trials,11,31 patients who
weremedically unfit for open surgical repair were essentially
excluded from the randomization process. In the UK trial,
the determination of fitness for surgery was left to the
discretion of the local physicians participating in the trial.32
Guidelines for high-risk criteria, such as poor cardiac or
respiratory status, were suggested but the presence or ab-
sence did not definitively determine trial eligibility. Inmany
retrospective analyses, investigators establish inclusion/ex-
clusion criteria based upon advanced age and coexisting
medical conditions, for which the database of choice may
be queried. There is now much information regarding
successful operations in high-risk individuals due to im-
provements in anesthetic options, surgical techniques, and
intensive care management.
Data from recent prospective, randomized trials evalu-
ating elective AAA repair provides compelling Level One
evidence for performing EVAR in patients “judged fit for
open repair”.11,31 Patients who were not deemed “medi-
cally fit for open repair” were then placed into EVAR Trial
2 in which patients were randomized to EVAR or no
intervention. Within the high-risk cohort, twenty-five per-
cent of the patients randomized to observation ultimately
underwent aneurysm repair at the request of the patients or
treating physician. These post-randomization crossovers
may lead to bias if the crossover occurred in order to
potentially avoid a worse outcome. Thus, the inability to
evaluate the true effect of the “intervention”, EVAR or
surveillance, may have resulted. However, the EVAR Trial
2 authors do state that an per protocol analysis demon-
strated similar results. Many reasons may exist for the
reported mortality rates in either group: time interval be-
tween randomization and repair leading to ruptures prior
to repair, complex patient care secondary to coexisting
medical conditions, or lack of preoperative medical treat-
ments (statins and -blocker medication use). At 4 years of
follow-up, there was no difference in all-cause mortality
between the EVAR and no intervention patients.This is not
surprising as aneurysm-related events are not common
beyond the perioperative period and patients generally
succumb from causes unrelated to their AAA. Furthermore,
aneurysm-related deaths can only be accurately determined
by a post-mortem examination or rupture seen on an
imaging study prior to death. However, obtaining an au-
topsy is generally not a common occurrence especially if a
patient dies outside of a hospital setting.
JOURNAL OF VASCULAR SURGERY
February 2007232 Bush et alSeveral studies have performed cost analyses and have
determined that EVAR is a more expensive treatment than
open aneurysm repair33-36 and no intervention.12 The
main difference in the two types of surgical repair is due to
the increased costs of endovascular grafts and the lifelong
surveillance and follow-up costs after EVAR none of which
were available to us through the NSQIP. In an analysis of
specific prospective studies, a recent Belgium document has
concluded that EVAR is not cost-effective, and thus, there
is not validation for widespread use.37 A full discussion on
health care reimbursement, and whether or not certain
costly procedures such as EVAR should be restricted, is
beyond the scope of this manuscript.
Equal opportunities for good surgical outcomes do not
exist among all persons. Circumstances transpire where a
person’s illness or disability significantly reduce their op-
portunity to respond to a therapy, such as any of the criteria
that we used in our definition of a high-risk surgical patient.
Society is not obligated to spend whatever it must to
provide them with such a therapy. However, society is
obligated to provide persons with the chance to optimize
their enjoyment of life, within the constraints of their
disease or disability. In some, the presence of a large or
expanding aneurysm, may contribute significantly to their
psychological ability to enjoy life, as well as knowing that
the outcomes following ruptured AAA repair remain dis-
mal. Quality of life is not reported to the NSQIP but most
recent studies have shown that though quality of life is
improved in the perioperative period following EVAR
compared to open repair, there is no difference when
patients are surveyed at remote time points.12,38,39 It is
clear from these published studies that EVAR is associated
with early improvements in physical mobility and pain as
well as a likelihood for a patient to be discharged to home
rather than an institution.40,41 Rationing parameters for
health care resources are admittedly controversial and gen-
erate ethical dilemmas. It has been suggested that perhaps
EVAR should be restricted to those patients who are “fit”
for surgery, by whatever definition deemed appropriate, as
the procedure, the endovascular devices, the continuing
need for surveillance imaging, and possible secondary rein-
terventions are costly.
Decidedly, there are several limitations to our analysis
in addition to the deficiencies inherent in a retrospective
design. Furthermore, direct comparisons to current pub-
lished literature are impossible due to dissimilarities in
study design and content of data collected. Our compari-
son was between EVAR and open repair as we do not have
a surveillance arm for control comparison. As previously
stated, the NSQIP does not contain aneurysm size which
has been shown to correlate with outcomes. Additionally,
we do not have cause of death and hence, use the term
“all-cause mortality” in stating our results. The use of the
BIRLS database, which contains death dates regardless
whether or not the death occurs in a VA facility, has been
demonstrated to miss approximately 5% to 10% of veteran
decedents.42 Nonetheless, we have no reason to believe
that more EVAR deaths than open deaths were overlookedin our study. Lastly, patients served at VA hospitals are
predominantly men. One might suggest that our results
could be positively biased as women may have worse results
after elective AAA repair (either open or EVAR). However,
the proportion of men is the same for both cohorts.
CONCLUSIONS
In the absence of a prospective, randomized trial, this
large patient cohort, representing routine clinical practice,
demonstrated the superiority of endovascular repair over
open repair in veterans deemed high risk for surgical ther-
apy. Our outcomes after elective EVAR are excellent, al-
though we compared EVAR with open repair and did not
have a surveillance arm10 for comparison. Our data dem-
onstrate that patients with considerable medical comor-
bidities and abdominal aortic aneurysms benefit from and
should be considered for primary EVAR.
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Dr Gregorio Sicard (St. Louis, Mo). I really congratulate Dr
Bush for this excellent paper. The NSQIP database is serving as a
model for outcomes assessment. It has the uniqueness of risk
adjustment, which is one of the issues that has always haunted
outcomes assessment. I would like to state that I am really glad to
see that the results of Dr Bush’s evaluation were not that dissimilarpatients in the IDE trials, (ie, the 29% mortality in the EVAR arm
of the high-risk surgical group.).
I do have a question for Dr Bush. When you looked at the
EVAR versus open at one year, were you able to determine if this
was all-cause mortality or aneurysm-related mortality?
Dr Ruth L. Bush. The death data in the BIRLS database,
the veterans’ beneficiary database, only answers the question,
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contain any information on what caused the death. We have
proposed looking at the National Death Index, which is avail-
able via linkage with Social Security numbers to determine cause
of death. However, the problem even with this data set is that,
for determining aneurysm-related death, autopsy rates are so
low that a lot of assumptions are made and speculations on what
is the cause of death, so we decided to only analyze all-cause
mortality.
Dr Sicard. And since this is a data set that is very robust in risk
adjustments, did you do any univariate or multivariate analysis to
identify what were those risk factors that could predict or that have
an association with mortality?
Dr Bush. In this particular study, we did not. In our first
study, now published in the Journal of the American College of
Surgeons, we looked at the endovascular versus open repair in all
elective cases listed in the NSQIP database. In this study we looked
at factors that may be independent predictors of outcome. We
found that advanced age, especially over 80, was associated with
mortality as was a history of stroke, smoking, and liver disease. And
we created a separate variable for hospital volume. In this study,
low-volume hospitals, in univariate analysis, were predictive of
mortality. However, in our multivariate analyses, this variable was
not significant.
Dr Sicard. Again, congratulations, and I hope all the mem-
bers that are here will attend this Saturday’s session because we will
be looking at different levels of evidence exactly on this issue of
high-risk patients.
Dr Robert Cambria (Bangor, Me). I had a simple question
about the definition of high risk. Looking at your slides, I don’t
think I see any low-risk patients based on those criteria. How
many procedures were excluded, both in the EVAR and open
category, for not being high risk, if you have that information?
Dr Bush. I do. During the time frame we looked at, fromMay
2001 through December 2004, there were about 3400 elective
aneurysm repairs performed at that time in VA hospitals. Of these,
2400 patients fit our high-risk criteria. We found that in our first
study, again, when we looked at the whole cohort together,
probably 75% of our patients in that original cohort could be
identified as a high risk, so we made the definition fairly strict for
this study. VA patients have been suggested to have more comor-
bidities and this may account for our relatively high-risk population
overall.
Dr George Geroulakos (London, United Kingdom). I won-
der whether you considered that perhaps the population of high
patients (EVAR 2) comparing EVAR with medical follow-uprisk, as you defined it, is not entirely comparable to the EVAR 2;
therefore, you cannot draw the conclusion that is written in the
abstract that high-risk patients could be considered safely, or
relatively safely, for intervention. To give you an example, you said
that a history of coronary artery bypass graft was considered as one
of the risk factors that makes patients to belong to the high-risk
group; while, in fact, what we’re trying to do is to convert these
high-risk factors to low-risk factors. So if a patient had coronary
artery bypass grafts and remained asymptomatic, he would not be
considered anymore, as far as risk factor is concerned, to a high-risk
group.
Dr Bush. You are absolutely right. One of the problems with
looking at administrative databases is, indeed, what is the defini-
tion of the variables being entered into the database as well as the
consistency of data entry? Furthermore, the data entry relies on the
people that are putting in the data. For example, a patient who is
undergoing coronary revascularization, or has had this procedure,
may or may not be completely now symptom-free or free from
coronary disease after their bypass.
The NSQIP database, it is a robust validated database. The
data are being entered by trained nurse abstractors who are con-
tinually audited by the Department of Veteran Affairs, and they
have strict definitions of actually what goes into the database. So
it’s more than just ICD-9 codes within that database.
But you are correct, I do not know if the patients are symptom-
free or still symptomatic following their coronary revascularization.
Dr Michel Makaroun (Pittsburgh, Pa). To my knowledge,
this is probably the first time I see a long-term survival curve from
all-cause mortality with a significant advantage of the endovascular
group over the open group long term. And I did not even see the
early separation in the first year that is very typical of these curves.
Do you have an explanation why your results are so different than
the usual analysis of one versus the other?
Dr Bush. That’s a very good point, and we did see our
patients demonstrating a benefit of endovascular repair and we
also saw that in all the patients as well, not just those that fit our
high-risk criteria. With the BIRLS database, we had death
information on almost every patient. We found that very few
patients had unavailable information. So our number of patients
at risk at the beginning is the same as the number of patients at
the end of the 2 years who are at risk. So it may be part of the
lack of data censorship in our survival curves that makes this
difference.INVITED COMMENTARYGregorio A. Sicard, MD, St. Louis, Mo
The treatment of infrarenal aortic aneurysm (AAA) in the
high-risk patient remains a challenge. The clinical introduction
of endovascular aneurysm repair (EVAR) offers the benefits of a
less invasive technique that was originally intended to expand
treatment to patients previously deemed not surgical candi-
dates.
During the last decade, many single-center and registry
series have consistently demonstrated a perioperative mortality
and morbidity benefit of EVAR compared with conventional
open repair (COR). Subgroup analyses of the high-risk patient
cohorts have shown a similar benefit of EVAR over COR. What
have been missing from the literature are uniformity, objectiv-
ity, and a precise definition of what constitutes a high-risk
patient. Scoring systems have been proposed for COR, but in
general, they do not apply to high-risk patients.1 Furthermore,
none of the scoring systems for high-risk patients treated with
EVAR have been validated.
A recently published randomized clinical trial of high-riskshowed a high perioperative mortality (9%) in the treatment arm
and no survival advantage at 4 years between EVAR and the
medical follow-up arm.2 Some concerns have been raised about
whether the results of this randomized clinical trial should be
extrapolated to all “unfit-for-surgery” AAA patients. A high mor-
tality in the EVAR randomized group and a lowmortality of EVAR
in the no-treatment group who crossed over to EVAR has raised
questions about the validity of the conclusions in this trial.
Bush and colleagues evaluate the results of EVAR versus
COR in the high-risk patients in the National Surgical Quality
Improvement Program, a large, national, validated, highly au-
dited database. The lower 30-day and 1-year all-cause mortality
in the EVAR compared with the COR group concurs with the
recently published Society for Vascular Surgery Outcomes
Committee’s analysis of the high-risk patients in the investiga-
tional device exemption United States Food and Drug Admin-
istration EVAR trials.3 Bush and colleagues attempt to further
stratify the results of the high-risk population by separately
analyzing the American Society of Anesthesiologists class 4
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demonstrated a perioperative and 1-year survival benefit over
open repair.
Most investigators agree that some high-risk patients do not
benefit from either COR or EVAR. The objective identification of
those patients remains a great challenge, primarily because of the
many variables to consider. The international vascular community
should come together to establish and validate a scoring system
with objective definitions that reproducibly predict outcomes in
high-risk patients with AAA.REFERENCES
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complication variables and definitions
1. Cardiac
Cardiac arrest requiring CPR
● Absence of cardiac rhythm or presence of chaotic cardiac
rhythm (ie,. ventricular fibrillation) requiring CPR
Myocardial infarction
● New transmural acute myocardial infarction occurring
within 30 days of surgery
2. Neurologic
Cerebrovascular accident/stroke
● New stroke
Coma
● Impaired level of consciousness for 24 hours
Peripheral nerve injury
● As stated (either sensory or motor)
3. Pulmonary
Failure to wean 48 hours
● On ventilator 48 hours postoperative
Pneumonia
● CDC definition
Pulmonary embolism
● Either high probability VQ scan, positive pulmonary
angiogram, or a positive CT scan
Reintubation for respiratory/cardiac failure
● Unplanned intubation after surgery
4. Renal
Acute renal failure
● Worsening renal function requiring hemodialysis,
ultrafiltration, or peritoneal dialysis
Progressive renal insufficiency
● Rise of creatinine of 2 mg/dL from preoperative value
Urinary tract infection
● CDC definition
5. Wound
Deep wound surgical site infection
● CDC definition
Superficial surgical site infection
● CDC definition
Wound disruption or dehiscence
● Disruption of the fascia
6. Bleeding requiring 4 units RBC
● Any transfusion of packed RBCs given from the time the
patient leaves the operating room
7. Graft failure
● Mechanical failure of a vascular graft or prosthesis
CPR, cardiopulmonary resuscitation; CDC, Centers for Disease Control
and Prevention; VQ, ventilation perfusion; CT, computed tomography;
RBC, red blood cells.
